REFERENCES
- Gunnell D, Frankel S.. Prevention of suicide: aspirations and evidence. BMJ. 1994; 308: 1227–33. [PUBMED], [INFOTRIEVE]
- Tondo L, Hennen J, Baldessarini R J. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 2001; 104: 163–72. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Meltzer H Y.. Suicide and schizophrenia: clozapine and the InterSePT study. J Clin Psychiatry. 1999; 60(suppl 12)47–50. [PUBMED]
- Meltzer H Y, Alphs L, Green A I, Altamura A C, Anand R, Bertoldi A, et al, InterSePT Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003; 60: 82–91. [PUBMED], [INFOTRIEVE]
- World Health Organization. The world health report 2001. Mental health: new understanding, new hope. Geneva, WHO. 2001
- Van Praag H M. Why has the antidepressant era not shown a significant drop in suicide rates?. Crisis. 2002; 23: 77–82. [PUBMED], [INFOTRIEVE]
- Pincus H A, Tanielian T L, Marcus S C, Olfson M, Zarin D A, Thompson J, et al, Prescribing trends in psychotropic medications. JAMA. 1998; 279: 526–31. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Isacsson G, Bergman U, Rich C L. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord. 1996; 41: 1–8. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Isacsson G.. Suicide prevention—a medical breakthrough?. Acta Psychiatr Scand. 2000; 102: 113–7. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ohberg A, Vuori E, Klaukka T, Lonnqvist J.. Antidepressants and suicide mortality. J Affect Disord. 1998; 50: 225–33. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Carlsten A, Waern M, Ekedahl A, Ranstam J.. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001; 10: 525–30. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Rihmer Z, Appleby L, Rihmer A, Belso N.. Decreasing suicide in Hungary [Letter]. Br J Psychiatry. 2000; 177: 84, [CROSSREF], [PUBMED], [INFOTRIEVE]
- Barbui C, Campomori A, D'Avanzo B, Negri E, Garattini S.. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol. 1999; 34: 152–6. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Olfson M, Shaffer D, Marcus S C, Greenberg T.. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003; 60: 978–82. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Angst F, Stassen H H, Clayton P J, Angst J.. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002; 68: 167–81. [CROSSREF], [PUBMED], [INFOTRIEVE]
- De, Leo D.. Why are we not getting any closer to preventing suicide?. Br J Psychiatry. 2002; 181: 372–4
- Rutz W, von, Knorring L, Walinder J.. Frequency of suicide in Gotland after systematic postgraduate education of general practitioners. Acta Psychiatr Scand. 1989; 80: 151–4. [PUBMED], [INFOTRIEVE]
- Baldessarini R J, Tondo L, Hennen J.. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann NY Acad Sci. 2001; 932: 24–38. [PUBMED], [INFOTRIEVE]
- Baca-Garcia E, Diaz-Sastre C, Basurte E, Prieto R, Ceverino A, Saiz-Ruiz J, et al, A prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. J Clin Psychiatry. 2001; 62: 560–4. [PUBMED], [INFOTRIEVE]
- Michaelis B H, Goldberg J F, Davis G P, Singer T M, Garno J L, Wenze S J.. Dimensions of impulsivity and aggression associated with suicide attempts among bipolar patients: a preliminary study. Suicide Life Threat Behav, (in press).
- Rifkin A, Quitkin F, Carrillo C, Blumberg A G, Klein D F. Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry. 1972; 27: 519–23. [PUBMED], [INFOTRIEVE]
- Wickham E A, Reed R V. Lithium for the control of aggressive and self-mutilating behavior. Int Clin Psychopharmacol. 1977; 2: 181–90
- Tondo L, Baldessrini R J, Hennen J, Gianfranco F, Silvetti F, Tohen M.. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998; 59: 404–14
- Van, Praag H M.. Depression, aggression, and anxiety: a biological hypothesis about their interrelation. Eur Neuropsychopharmacol. 1992; 2: 393–402
- Schou M.. The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. J Affect Disord. 1998; 50: 253–9. [PUBMED], [INFOTRIEVE]
- Baldessarini R J, Tondo L, Hennen J.. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2003; 64(suppl 5)44–52. [PUBMED], [INFOTRIEVE]
- Bochetta A, Arday R, Burrai C, Chillo tiC, Quesada G, Del, Zompo M.. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol. 1998; 18: 384–9
- Nilsson A.. Lithium therapy and suicide risk. J Clin Psychiatry. 1999; 60(suppl 2)85–8. [PUBMED], [INFOTRIEVE]
- Müller-Oerlinghausen B, Wolf T, Ahrens B, Glaenz T, Schou M, Grof E, et al, Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-Treated Patients (IGSLI). Acta Psychiatr Scand. 1996; 94: 333–47
- Prien R F, Klett C J., Caffey E M. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry. 1974; 131: 198–203. [PUBMED], [INFOTRIEVE]
- Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W.. Effect of prophylactic treatment on suicide risk in patients with major affective disorder. Pharmacopsychiatry. 1996; 29: 103–7. [PUBMED], [INFOTRIEVE]
- Greil W, Ludwig-Mayerhofer W, Steller B, Czernik A, Giedke H, Müller-Oerlinghausen, et al, The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J Affect Disord. 1993; 28: 257–65. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Greil W, Ludwig-Mayerhofer W, Brazo N, Schöchlin C, Schmidt S, Engel R R, et al, Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomized study. J Affect Disord. 1997; 43: 151–61. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Goodwin F K, Fireman B, Simon G E, Hunkeler E M, Lee J, Revicki D.. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003; 290: 1467–73. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Coryell W, Arndt S, Turvey C, Endicott J, Solomon D, Mueller T, et al, Lithium and suicidal behavior in major affective disorder: a case-control study. Acta Psychiatr Scand. 2001; 104: 193–7. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Müller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, et al, The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand. 1992; 86: 218–22
- Müller-Oerlinghausen B, Wolf T, Ahrens B, Schou M, Grof E, Grof P, et al, Mortality during initial and during later lithium treatment. Acta Psychiatr Scand. 1994; 90: 295–7
- Coppen A, Standish-Barry H, Bailey J, Houston G, Sicocks P, Hermon C.. Does lithium reduce the mortality of recurrent mood disorders?. J Affect Disord. 1991; 23: 1–7. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ahrens B, Müller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, et al, Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord. 1995; 33: 67–75. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Norton B, Whalley L.. Mortality of a lithium-treated population. Br J Psychiatry. 1984; 145: 277–82. [PUBMED], [INFOTRIEVE]
- Vestergaard P, Aagaard J.. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord. 1991; 21: 33–8. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Nilsson A.. Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients, Pharmacopsychiatry. 1995; 28: 8–13
- Brodersen A, Licht R W, Vestergaard P, Olesen A V, Mortensen P B. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry. 2000; 176: 429–33. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ahrens B, Müller-Oerlinghausen B.. Does lithium exert an independent antisuicidal effect?. Pharmacopsychiatry. 2001; 34: 132–6. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Swann A C, Bowden C L, Morris D, Calabrese J R, Petty F, Small J, et al, Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997; 54: 37–42. [PUBMED], [INFOTRIEVE]
- Bowden C L, Calabrese J R, Sachs G, Yatham L N, Asghar S A, Hompland M, et al, Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60: 392–400. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Calabrese J R, Bowden C L, Sachs G, Yatham L N, Behnke K, Mehtonen O-P, et al, Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64: 1013–24. [PUBMED], [INFOTRIEVE]
- Goldberg J F, Garno J L, Leon A C, Kocsis J H, Portera L.. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999; 60: 733–40. [PUBMED], [INFOTRIEVE]
- Tsai S Y, Lee J C, Chen C C.. Characteristics and psychosocial problems of patients with bipolar disorder at high risk for suicide attempt. J Affect Disord. 1999; 52: 145–52. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Tondo L, Baldessarini R J, Hennen J, Minnai G P, Salis P, Scamonatti L, et al, Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry. 1999; 60(suppl 2)63–9. [PUBMED], [INFOTRIEVE]
- Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999; 60: 79–88. [PUBMED], [INFOTRIEVE]
- Yerevenian B I, Koek R J, Mintz J.. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J Affect Disord. 2003; 73: 223–8
- Endick C J, Goldberg J F, Allen M H, Sagduyu K, Michaelis B H, Singer T M, et al, Correlates of suicidal ideation in the STEP-500 bipolar cohort, Poster presented at the annual meeting of the American Psychiatric Association, San Francisco, CA. May 2003
- Cowdry R W, Gardner D L. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988; 45: 111–9. [PUBMED], [INFOTRIEVE]
- Bowden C L, Brugger A M, Swann A C, Calabrese J R, Janicak P G, Petty F, et al, Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994; 271: 918–24. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Lambert P A, Venaud G.. Utilisation de valpromise en therapeutique psychiatrique. Encephale. 1987; 8: 367–73
- Bowden C L, Calabrese J R, McElroy S L, Gyulai L, Wassef A, Petty F, et al, A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000; 57: 481–9. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Gyulai L, Bowden C L, McElroy S L, Calabrese H R, Petty F, Swann A C, et al, Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacol. 2003; 28: 1374–82
- Bowden C, Calabrese J, Nemeroff C, Lydiard R B, McElroy S.. Effects on suicidality of divalproex, lithium and placebo in randomized one-year maintenance treatment of bipolar disorder, Poster presented at annual meeting of the NIMH New Clinical Drug Evaluation Unit, Boca Raton, FL. June 1998
- Hussar A E. Effect of tranquilizers on medical morbidity and mortality in a mental hospital. JAMA. 1962; 179: 682–6. [PUBMED], [INFOTRIEVE]
- Beisser A R, Blanchette J E. A study of suicides in a mental hospital. Dis Nerv Syst. 1961; 22: 365–9. [PUBMED], [INFOTRIEVE]
- Winokur G, Tsuang M.. The Iowa 500: suicide in mania, depression, and schizophrenia. Am J Psychiatry. 1975; 132: 650–1. [PUBMED], [INFOTRIEVE]
- Kerwin R.. Preventing suicide [Correspondence]. Br J Psychiatry. 2003; 182: 366, [CROSSREF], [PUBMED], [INFOTRIEVE]
- Roy A, Karoum F, Pollack S.. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry. 1992; 49: 447–50. [PUBMED], [INFOTRIEVE]
- Caldwell C B, Gottesman I I. Schizophrenia—a high risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav. 1992; 22: 479–93. [PUBMED], [INFOTRIEVE]
- Altamaura A C, Bassetti R, Bignotti S, Pioli R, Mundo E.. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res. 2003; 60: 47–55
- Heilä H, Isometsä E T, Henriksson M M, Heikkinen M E, Marttunen M J, Lönnqvist J K. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry. 1999; 60: 200–8
- Meltzer H Y.. Treatment of suicidality in schizophrenia. Ann NY Acad Sci. 2001; 932: 44–60. [PUBMED], [INFOTRIEVE]
- Meltzer H Y, Okayli G.. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995; 152: 183–90. [PUBMED], [INFOTRIEVE]
- Shear M K, Allen F, Weiden P.. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol. 1983; 3: 235–6. [PUBMED], [INFOTRIEVE]
- Blum A.. Patients at risk of developing severe side effects from depot fluphenazine treatment. Am J Psychiatry. 1980; 137: 254–5. [PUBMED], [INFOTRIEVE]
- Drake R E, Ehrlich J.. Suicide attempts associated with akathisia. Am J Psychiatry. 1985; 142: 499–501. [PUBMED], [INFOTRIEVE]
- Weiden P.. Akathisia from prochlorperazine [Letter]. JAMA. 1985; 253: 635, [CROSSREF], [PUBMED], [INFOTRIEVE]
- Schulte J R.. Homicide and suicide associated with akathisia and haloperidol. Am J Forensic Psychiatry. 1985; 6: 3–7
- Shaw E D, Mann J J, Weiden P J, Sinsheimer L M, Brunn R D. A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study [Letter]. J Clin Psychopharmacol. 1986; 6: 196–7. [PUBMED], [INFOTRIEVE]
- Planansky K, Johnston R.. The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatr Scand. 1971; 47: 473–83. [PUBMED], [INFOTRIEVE]
- Farberow N, Shneidman E, Leonard C.. Suicide among schizophrenic hospital patients. Farberow N, Shneidman E. The cry for help. New York, McGraw-Hill. 1965
- van, Putten T, Mutalipassi L R, Malkin M D. Phenothiazine-induced decompensation. Arch Gen Psychiatry. 1974; 30: 102–5. [PUBMED], [INFOTRIEVE]
- van, Putten T.. The many faces of akathisia. Compr Psychiatry. 1975; 16: 43–6. [CROSSREF]
- van, Putten T, Marder S R.. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 1987; 48(9 suppl)13–9. [PUBMED], [INFOTRIEVE]
- Rifkin A, Quitkin F, Klein D F. Akinesia: a poorly recognized drug-induced extrapyramidal behavior disorder. Arch Gen Psychiatry. 1975; 32: 672–4
- Siris S G, Morgan V, Fagerström R, Rifkin A, Cooper T B. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry. 1987; 44: 533–9. [PUBMED], [INFOTRIEVE]
- Hogan T P, Awad A G.. Pharmacotherapy and suicide risk in schizophrenia. Can J Psychiatry. 1983; 28: 277–81. [PUBMED], [INFOTRIEVE]
- Cheng K K, Leung C M, Lo W H, Lam T H. Risk factors of suicide among schizophrenics. Acta Psychiatr Scand. 1990; 81: 220–4. [PUBMED], [INFOTRIEVE]
- Waddington J L, Yousseff H A, Kinsella A.. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study, Br J Psychiatry. 1998; 173: 325–9
- Montout C, Casadebaig F, Lagnaoui R, Verdoux H, Philippe A, Begaud B, et al, Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res. 2002; 57: 146–56
- Heikkila L, Eliander H, Vartianinen H, Turunen M, Pedersen V.. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study, Curr Med Res Opin. 1992; 12: 594–603
- Montgomery S A.. Suicide and antidepressants. Ann NY Acad Sci. 1997; 836: 329–38. [PUBMED], [INFOTRIEVE]
- Taiminen T J. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand. 1993; 87: 45–7. [PUBMED], [INFOTRIEVE]
- Taiminen T J, Kujari H.. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. Acta Psychiatr Scand. 1994; 90: 247–51. [PUBMED], [INFOTRIEVE]
- Warnes H.. Suicide in schizophrenics. Dis Nerv Ment Syst. 1968; 29(suppl)35–40
- Cohen S, Leonard C V, Farberow N, Shneidman E S.. Tranquilizers and suicide in the schizophrenic patient. Arch Gen Psychiatry. 1964; 11: 312–21. [PUBMED], [INFOTRIEVE]
- Roy A.. Suicide in chronic schizophrenia. Br J Psychiatry. 1982; 141: 171–7. [PUBMED], [INFOTRIEVE]
- Wilkinson G, Bacon N A. A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychol Med. 1984; 14: 899–912. [PUBMED], [INFOTRIEVE]
- Palmer D D, Henter I D, Wyatt R J. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia?. J Clin Psychiatry. 1999; 60: 100–3. [PUBMED], [INFOTRIEVE]
- Bebbington P E.. The content and context of compliance. Int Clin Psychopharmacol. 1995; 9(suppl 5)41–50. [PUBMED], [INFOTRIEVE]
- Heila H, Isometsa E T, Henriksson M M, Heikkinen M E, Marttunen M J, Lonnqvist J K. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry. 1999; 60: 200–8. [PUBMED], [INFOTRIEVE]
- Johnson D AW, Pasterski G, Ludlow J M, Street K, Taylor R DW. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983; 67: 339–52. [PUBMED], [INFOTRIEVE]
- Montgomery S A, Montgomery D B, Green M, Bullock T, Baldwin D.. Pharmacotherapy in the prevention of suicidal behavior. J Clin Psychopharmacol. 1992; 12: 27S–31S. [PUBMED], [INFOTRIEVE]
- Soloff P, George A, Nathan R, Schultz P, Resnik R, Hamer R, et al, Progress in pharmacotherapy of borderline disorders. A double blind study of amitriptyline, haloperidol and placebo. Arch Gen Psychiatry. 1986; 43: 691–7. [PUBMED], [INFOTRIEVE]
- Battaglia J, Wolff T K, Wagner-Johnson D S, Rush A J, Carmody T J, Basco M R. Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol. 1999; 14: 361–71. [PUBMED], [INFOTRIEVE]
- Spivak B, Mester R, Wittenberg N, Mamam Z, Weizman A.. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol. 1997; 20: 442–6. [PUBMED], [INFOTRIEVE]
- Khan A, Khan S R, Leventhal R M, Brown W A. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry. 2001; 158: 1449–54. [PUBMED], [INFOTRIEVE]
- Storosum J G, van, Zwieten B J, Wohlfarth T, de, Haan L, Khan A, van den, Brink W.. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry. 2003; 60: 365–8. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Walker A M, Lanza L L, Arellano F, Rothman K J. Mortality in current and former users of clozapine. Epidemiology. 1997; 8: 671–7. [PUBMED], [INFOTRIEVE]
- Reid W H, Mason M, Hogan T.. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv. 1998; 49: 1029–33. [PUBMED], [INFOTRIEVE]
- Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R.. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry. 1999; 175: 576–80. [PUBMED], [INFOTRIEVE]
- Duggan A, Warner J, Knapp M, Kerwin R.. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia. Brit J Psychiatry. 2003; 182: 505–8
- Sernyak M J, Desai R, Stolar M, Rosenheck R.. Impact of clozapine on completed suicide. Am J Psychiatry. 2001; 158: 931–7. [CROSSREF], [INFOTRIEVE]
- Meltzer H.. Clozapine and suicide [Letter]. Am J Psychiatry. 2002; 159: 323–4. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ertugrul A.. Clozapine and suicide [Letter]. Am J Psychiatry. 2002; 159: 323, [CROSSREF], [PUBMED], [INFOTRIEVE]
- Vangala V R, Brown E S, Suppes T.. Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord. 1999; 2: 123–4
- Frye M A, Ketter T A, Althsuler L L, Denicoff K D, Dunn R T, Kimbrell T A, et al, Clozapine in bipolar disorder: treatment implications for atypical antipsychotics. J Affect Disord. 1998; 48: 91–104. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Nàhunek K, Rodovà A, Svestka J, Kamenicka V, Ceskova E, Misurec J.. Clinical experience with clozapine in endogenous depression [Letter]. Activ Nerv Super. 1973; 15: 102
- Ranjan R, Meltzer H Y.. Acute and long term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry. 1996; 40: 253–8. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush A J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999; 156: 1164–9. [PUBMED], [INFOTRIEVE]
- [Collaborative Working Group on Clinical Trial Evaluations], Atypical antipsychotics for the treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry. 1998; 59: 41–5
- Spivak B, Shabash E, Sheitman B, Weizman A, Mester R.. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry. 2003; 64: 755–60. [PUBMED], [INFOTRIEVE]
- Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E.. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998; 59(suppl 3)103–7. [PUBMED], [INFOTRIEVE]
- Zhang W, Perry K W, Wong D T, Potts B D, Bao J, Tollefson G D, et al, Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000; 23: 250–62. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Shelton R C, Tollefson G D, Tohen M, Stahl S, Gannon K S, Jacobs T G, et al, A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001; 158: 131–4. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Tran P V, Hamilton S H, Kuntz A J, Potvin J H, Andersen S W, Beasley C, Jr, et al, Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychiatry. 1997; 17: 407–18
- Glazer W M.. Formulary decisions and health economics. J Clin Psychiatry. 1998; 59(suppl 19)23–9. [PUBMED], [INFOTRIEVE]
- Beasley C M, Sayler M E, Kiesler G M, Potvin J H, Sanger T M, Tollefson G D.. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia [Abstract]. Schizophr Res. 1998; 29: 28
- Müller-Siecheneder F, Müller M J, Hillert A, Szegedi A, Wetzel H, Benkert O.. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol. 1998; 18: 111–20
- Viner M W, Yixiang C, Bakshi I, Kamper P.. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol. 2003; 23: 104–6. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Margolese H C, Annable L, Dion Y.. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychiatry. 2002; 63: 1040–4. [PUBMED], [INFOTRIEVE]
- Keck P E, Jr, Reeves K R, Harrigan E P. Ziprasidone Study Group, Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001; 21: 27–35. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Emsley R A., Buckley P., Jones A M., Greenwood M R. Differential effect of quetiapine on partially responsive schizophrenia. J Psychopharmacol. 2003; 17: 210–5. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Kessler R D, McGonagle K A, Zhao S, Nelson C B, Hughes M, Eshleman S, et al, Lifetime and 12-month prevalence of DSM-IIII-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994; 51: 8–19. [PUBMED], [INFOTRIEVE]
- Matthews J D, Fava M.. Risk of suicidality in depression with serotonergic antidepressants. Ann Clin Psychiatry. 2000; 12: 43–50. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Regier D A, Moscicki E K.. Reduction of the suicide rate in young people: progress review. Washington, DC, U.S. Department of Health and Human Services. 1987
- Goodwin F K, Jamison K R.. Manic-depressive illness. New York, Oxford University Press. 1990
- Coccaro E F, Kavoussi R J.. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997; 54: 1081–8. [PUBMED], [INFOTRIEVE]
- Montgomery S A, Dunner D L, Dunbar G C. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol. 1995; 5: 5–13. [PUBMED], [INFOTRIEVE]
- Beasley C M, Jr, Koke S C, Nilsson M E, Gonzales J S. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther. 2000; 22: 1319–30. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Letizia C, Kapik B, Flanders W D. Suicidal risk during controlled clinical investigations of fluvoxamine. J Clin Psychiatry. 1996; 59: 415–21
- Tollefson G D, Fawcett J, Winokur G, Beasley C M, Jr, Potvin J H, Faries D E, et al, Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann Clin Psychiatry. 1993; 5: 209–24. [PUBMED], [INFOTRIEVE]
- Wernicke J F, Sayler M E, Koke S C, Pearson D K, Tollefson G D.. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depress Anxiety. 1997; 6: 31–9. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Muijen N, Roy D, Silverstone T, Mehmet A, Christie M.. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed patients. Acta Psychiatr Scand. 1988; 78: 384–90. [PUBMED], [INFOTRIEVE]
- Georgotas A, McCue R E, Friedman E, Cooper T B. Response of depressive symptoms to nortriptyline, phenelzine and placebo. Br J Psychiatry. 1987; 151: 102–6. [PUBMED], [INFOTRIEVE]
- Verkes R J, Van der, Mast R C, Hengeveld M W, Tuyl J P, Zwinderman A H, Van Kempen G MJ. Reduction of paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998; 155: 543–7. [PUBMED], [INFOTRIEVE]
- Cornelius J R, Soloff P H, Perel J M, Ulrich R F. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol. 1991; 11: 116–20. [PUBMED], [INFOTRIEVE]
- Markovitz P J, Calabrese J R, Schulz S C, Meltzer H Y. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry. 1991; 148: 1064–7. [PUBMED], [INFOTRIEVE]
- Montgomery S A, Roy D, Montgomery D B.. The prevention of recurrent suicidal acts. Br J Clin Pharmacol. 1983; 15: 183S–8S. [PUBMED], [INFOTRIEVE]
- Soloff P H, George A, Nathan R S, Schulz P M, Perel J M. Parodoxical effects of amitriptyline on borderline patients. Am J Psychiatry. 1986; 143: 1603–5. [PUBMED], [INFOTRIEVE]
- Khan A, Warner H A, Brown W A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000; 57: 311–7. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Khan A, Khan S, Kolts R, Brown W A. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003; 160: 790–2. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Beasley C M, Jr, Dornseif B E, Bottomsworth J C, Sayler M E, Rampey A H, Jr, Heiligenstein J H, et al, Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991; 303: 685–92. [PUBMED], [INFOTRIEVE]
- Beasley C M, Jr, Faries D E, Sayler M E, Potvin J H.. Fluoxetine not associated with suicidality in international controlled clinical trials in depression. Clin Res. 1991; 39: 767A
- Wheadon D E, Rampey A H, Jr, Thompson V L, Potvin J H, Masica D N, Beasley C M, Jr. Lack of association between fluoxetine and suicidality in bulimia nervosa. J Clin Psychiatry. 1992; 53: 235–41. [PUBMED], [INFOTRIEVE]
- Goldstein D J, Rampey A H, Potvin J H, Masica D N, Beasley C M, Jr. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. J Clin Psychiatry. 1999; 54: 309–16
- Beasley C M, Jr, Potvin J H, Masica D N, Wheadon D E, Dornseif B E, Genduso L A. Fluoxetine: no association with suicidality in obsessive compulsive disorder. J Affect Disord. 1992; 24: 1–10. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Leon A C, Keller M B, Warshaw M G, Mueller T I, Solomon D A, Coryell W, et al, Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry. 1999; 156: 195–201. [PUBMED], [INFOTRIEVE]
- Tanum L.. Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand. 2000; 101(suppl 402)37–40
- Tec L, Bindelglas P M. The treatment of enuresis with imipramine. Am J Psychiatry. 1968; 125: 266–7. [PUBMED], [INFOTRIEVE]
- Rampling D.. Aggression: a paradoxical response to tricyclic antidepressants. Am J Psychiatry. 1978; 135: 117–8. [PUBMED], [INFOTRIEVE]
- Damluji N F, Ferguson J M. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol. 1998; 6: 77–92
- Teicher M H, Glod C, Cole J O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147: 207–10. [PUBMED], [INFOTRIEVE]
- Dasgupta K.. Additional cases of suicidal ideation associated with fluoxetine [Letter]. Am J Psychiatry. 1990; 147: 1570
- Wirshing W C, van, Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T.. Fluoxetine, akathisia and suicidality: is there a causal connection?. Arch Gen Psychiatry. 1992; 49: 580–91. [PUBMED], [INFOTRIEVE]
- Masand P, Gupta S, Dewan M.. Suicidal ideation related to fluoxetine treatment [Letter]. N Engl J Med. 1991; 324: 420, [PUBMED], [INFOTRIEVE]
- Rothschild A J, Locke C A. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry. 1991; 52: 491–3. [PUBMED], [INFOTRIEVE]
- Vorstman J, Lahuis B, Buitelaar J K. SSRIs associated with behavioral activation and suicidal ideation. J Am Acad Child Adol Psychiatry. 2001; 40: 1364–5
- Waechter F.. Paroxetine must not be given to patients under 18. BMJ. 2003; 326: 1282, [CROSSREF], [PUBMED], [INFOTRIEVE]
- Abbott A.. British panel bans use of antidepressant in treat children. Nature. 2003; 423: 792, [PUBMED], [INFOTRIEVE]
- Lindgren T, Kantak K M. Effects of serotonin receptor agonists and antagonists on offensive aggression in mice. Aggressive Behav. 1987; 13: 87–96
- Mann J J, Kapur S.. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry. 1991; 48: 1027–33. [PUBMED], [INFOTRIEVE]
- Mann J J, Arango A, Marzuk P M, Theccanat S, Reis D J. Evidence for the 5-HT hypothesis of suicide: a review of post-mortem studies. Br J Psychiatry. 1989; 155: 7–14
- Hansen L, Wilkinson D G. Drug induced akathisia, suicidal ideation and its treatment in the elderly. Int J Geriatr Psychiatry. 2001; 16: 230–6
- Lipinski J F, Mallya G, Zimmerman P.. Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989; 50: 339–42. [PUBMED], [INFOTRIEVE]
- Zubenko G S, Cohen B M, Lipinski J F. Anti-depressant-related akathisia. J Clin Psychopharmacol. 1987; 7: 254–7. [PUBMED], [INFOTRIEVE]
- Hamilton M, Opeler L A.. Akathisia, suicidality and fluoxetine. J Clin Psychiatry. 1992; 53: 401–6. [PUBMED], [INFOTRIEVE]
- Lane R M.. SSRI-induced EPS and akathisia: implications for treatment. J Psychopharmacol. 1998; 12: 192–214. [PUBMED], [INFOTRIEVE]
- Popli A, Gupta S.. Polypharmacy, akathisia and associated suicide attempts. Depression. 1993; 1: 53–5
- Tollefson G D, Rampey A H, Beasley C M, Jr, Enas G G, Potvin J H. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol. 1994; 14: 163–9. [PUBMED], [INFOTRIEVE]
- Rouillon F, Phillips R, Serrurier D, Ansart E, Gerard M J. Prophylactic efficacy of maprotiline on relapses of unipolar depression. Encephale. 1989; 15: 527–34. [PUBMED], [INFOTRIEVE]
- Fava M, Rosenbaum J F.. Suicidality and fluoxetine: is there a relationship?. J Clin Psychiatry. 1991; 52: 108–11. [PUBMED], [INFOTRIEVE]
- Warshaw M G, Keller M B. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry. 1996; 57: 158–66. [PUBMED], [INFOTRIEVE]
- Buchholtz-Hansen P E, Wang A G, Kragh-Sørensen O. Mortality in major affective disorder: relationship to subtype of depression. Danish University Antidepressant Group. Acta Psychiatr Scand. 1993; 87: 329–35. [PUBMED], [INFOTRIEVE]
- Dunbar G C, Cohn J B, Fabre L F, Feighner J P, Fieve R R, Mendels J, et al, A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry. 1991; 159: 394–8. [PUBMED], [INFOTRIEVE]
- Kapur S, Mieczkowski T, Mann J.. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992; 268: 3441–5. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Jick S S, Dean A D, Jick H.. Antidepressants and suicide. BMJ. 1995; 310: 215–8. [PUBMED], [INFOTRIEVE]
- Fischer S, Bryant S G, Kent T A. Postmarketing surveillance by patient self-monitoring: trazodone versus fluoxetine. J Clin Psychopharmacol. 1993; 13: 235–42
- Derby L E, Hershel J, Dean A D. Antidepressant drugs and suicide. J Clin Psychopharmacol. 1992; 12: 235–40. [PUBMED], [INFOTRIEVE]
- Montgomery S, Åsberg M, Montgomery D B.. Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmacol. 1978; 5: 77S–80S. [PUBMED], [INFOTRIEVE]
- Oquendo M A, Malone K M, Ellis S P, Sackeim H A, Mann J J. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry. 1999; 156: 190–4. [PUBMED], [INFOTRIEVE]
- Oquendo M A, Kamali M, Ellis S P, Grunebaum M F, Malone K M, Brodsky B S, et al, Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry. 2002; 159: 1746–51. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Isacsson G, Bergman U, Rich C L.. Antidepressants, depression and suicide: an analysis of the San Diego study. J Affect Disord. 1994; 32: 277–86. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Isacsson G, Holmgren P, Druid H, Bergman U.. The utilization of antidepressants—a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period of 1992–1994. Acta Psychiatr Scand. 1997; 96: 94–100. [PUBMED], [INFOTRIEVE]
- Isacsson G, Holmgren P, Druid H, Bergman U.. Psychotics and suicide prevention: implications from toxicological screening of 5281 suicides in Sweden 1992–1994. Br J Psychiatry. 1999; 174: 259–65. [PUBMED], [INFOTRIEVE]
- Andersen U A, Andersen M, Rosholm J U, Gram L F. Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand. 2001; 104: 458–65. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Henriksson S, Boëthius G, Isacsson G.. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jämtland county, Sweden, 1985–95. Acta Psychiatr Scand. 2001; 103: 301–6. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Marzuk P M, Tardiff K, Leon A C, Hirsch C S, Stajic M, Hartwell N, et al, Use of prescription psychotropic drugs among suicide victims in New York City. Am J Psychiatry. 1995; 152: 1520–2. [PUBMED], [INFOTRIEVE]
- Suominen K H, Isometsa E T, Henriksson M M, Ostamo A I, Lonnqvist J K. Inadequate treatment for major depression both before and after attempted suicide. Am J Psychiatry. 1998; 155: 1778–80. [PUBMED], [INFOTRIEVE]
- Wolf T, Müller-Oerlinghausen B, Ahrens B, Grof P, Schou M, Felber W, et al, How to interpret findings on mortality of long-term lithium-treated manic-depressive patients? Critique of different methodological approaches. J Affect Disord. 1996; 39: 127–32. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Akiskal H S.. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol. 1996; 16(2 suppl)4S–14S. [PUBMED], [INFOTRIEVE]
- Charney D S, Nemeroff C B, Lewis L, Laden S K, Gorman J M, Laska E M, et al, National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry. 2002; 59: 262–70. [CROSSREF], [PUBMED], [INFOTRIEVE]